Codexis, Inc.

Codexis, Inc., discovers, develops, enhances, and commercializes novel enzymes and other classes of proteins. The company is a provider of enzymatic solutions for therapeutics manufacturing and leveraging proprietary CodeEvolver evolution technology platform. The CodeEvolver platform technology develops enzymes for the synthesis of RNAi therapeutics through ECO Synthesis manufacturing platform. It also develops enzymes; and 450 RNAi therapeutic assets that are in Phase 2 and Phase 3 clinical trials that targets large disease indications such as Alzheimer’s, hyperlipidemia and hypertension. The company has a licensing agreement with Aldevron LLC (“Aldevron”), a manufacture of plasmid DNA, RNA and proteins; and a license agreement whereby Pfizer obtained a license to make a specific Codexis enzyme for use in the manufacture of Pfizer’s products. Codexis, Inc. was incorporated in 2002 and is headquartered in Redwood City, California.